ChemGenex Pharmaceuticals Limited Investigators Report Activity Of Ceflatonin(R) And Gleevec(R) Combination Therapy in CML Patients Resistant To Gleevec(R) Alone

MELBOURNE, Australia, & MENLO PARK, Calif.--(BUSINESS WIRE)--ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) announced today the presentation of new phase 2 clinical data supporting the use of Ceflatonin® (homoharringtonine or HHT) in combination with imatinib mesylate (Gleevec®) to treat chronic myeloid leukemia (CML) patients who have developed resistance to Gleevec® and other tyrosine kinase inhibitors.